ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and ...

– Cystic Fibrosis Foundation provides $3 million in new funding to accelerate development of inhaled mRNA therapy for cystic fibrosis – – Research collaboration with Praxis Precision Medicines (PRAX) ...

Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the ...

ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis – RCT2100 co-administered with ivacaftor will assess ...

Dr. Maki brings nearly 20 years of biotechnology and pharma business development expertise as Company rapidly advances its powerful LNP platform to deliver mRNA-based therapies MENLO PARK, Calif. & ...

ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and ...